Harrie E Buist

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5150580/publications.pdf

Version: 2024-02-01

23 papers	581 citations	623734 14 h-index	642732 23 g-index
23 all docs	23 docs citations	23 times ranked	886 citing authors

#	Article	IF	Citations
1	Development of good modelling practice for physiologically based pharmacokinetic models for use in risk assessment: The first steps. Regulatory Toxicology and Pharmacology, 2008, 50, 400-411.	2.7	91
2	Predicting blood:air partition coefficients using basic physicochemical properties. Regulatory Toxicology and Pharmacology, 2012, 62, 23-28.	2.7	77
3	Guidance on dermal absorption. EFSA Journal, 2017, 15, e04873.	1.8	62
4	Evaluation of an alternative in vitro test battery for detecting reproductive toxicants in a grouping context. Reproductive Toxicology, 2015, 55, 11-19.	2.9	37
5	New in vitro dermal absorption database and the prediction of dermal absorption under finite conditions for risk assessment purposes. Regulatory Toxicology and Pharmacology, 2010, 57, 200-209.	2.7	33
6	Risks to health and environment of the use of lead in products in the EU. Resources, Conservation and Recycling, 2006, 49, 89-109.	10.8	31
7	The OSIRIS Weight of Evidence approach: ITS for skin sensitisation. Regulatory Toxicology and Pharmacology, 2013, 67, 146-156.	2.7	30
8	Relative absorption and dermal loading of chemical substances: Consequences for risk assessment. Regulatory Toxicology and Pharmacology, 2009, 54, 221-228.	2.7	26
9	A high throughput screening system for predicting chemically-induced reproductive organ deformities. Reproductive Toxicology, 2015, 55, 95-103.	2.9	23
10	OSIRIS, a quest for proof of principle for integrated testing strategies of chemicals for four human health endpoints. Regulatory Toxicology and Pharmacology, 2013, 67, 136-145.	2.7	22
11	The OSIRIS Weight of Evidence approach: ITS for the endpoints repeated-dose toxicity (RepDose ITS). Regulatory Toxicology and Pharmacology, 2013, 67, 157-169.	2.7	19
12	Life-cycle assessment framework for indoor emissions of synthetic nanoparticles. Journal of Nanoparticle Research, 2015, 17, 1.	1.9	19
13	Hazard assessment of nitrosamine and nitramine by-products of amine-based CCS: Alternative approaches. Regulatory Toxicology and Pharmacology, 2015, 71, 601-623.	2.7	19
14	Derivation of health effect factors for nanoparticles to be used in LCIA. NanoImpact, 2017, 7, 41-53.	4.5	18
15	Effects of single and repeated exposure to biocidal active substances on the barrier function of the skin in vitro. Regulatory Toxicology and Pharmacology, 2005, 43, 76-84.	2.7	14
16	The OSIRIS Weight of Evidence approach: ITS mutagenicity and ITS carcinogenicity. Regulatory Toxicology and Pharmacology, 2013, 67, 170-181.	2.7	14
17	Comparative Human Health Impact Assessment of Engineered Nanomaterials in the Framework of Life Cycle Assessment. Risk Analysis, 2017, 37, 1358-1374.	2.7	13
18	Derivation of the minimal magnitude of the Critical Effect Size for continuous toxicological parameters from within-animal variation in control group data. Regulatory Toxicology and Pharmacology, 2009, 55, 139-150.	2.7	9

#	Article	IF	Citations
19	Evaluation of measures to mitigate mineral oil migration from recycled paper in food packaging. Packaging Technology and Science, 2020, 33, 531-546.	2.8	7
20	Dermatokinetics of didecyldimethylammonium chloride and the influence of some commercial biocidal formulations on its dermal absorption in vitro. Regulatory Toxicology and Pharmacology, 2007, 48, 87-92.	2.7	6
21	A Family of Waterâ€Immiscible, Dipolar Aprotic, Diamide Solvents from Succinic Acid. ChemSusChem, 2020, 13, 3212-3221.	6.8	6
22	Applicability of in silico tools for the prediction of dermal absorption for pesticides. EFSA Supporting Publications, 2018, 15, 1493E.	0.7	3
23	A TTC threshold for acute oral exposure to non-genotoxic substances. Regulatory Toxicology and Pharmacology, 2016, 76, 217-220.	2.7	2